Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

Enhertu showed significant improvement in pathologic complete response rates in high-risk HER2-positive early-stage breast cancer compared with standard care. The DESTINY-Breast11 trial indicated ...

May 15, 2025 — South African scientists have identified two new breast cancer genes -- RAB27A and USP22 -- in Black women, marking the first GWAS of its kind on the continent. This breakthrough ...

“These topline results from DESTINY-Breast11 demonstrate that Enhertu followed by THP could offer patients with HER2-positive breast cancer a promising new treatment approach prior to ...

The surprise of the diagnosis was her main motivator, but she also knew that — as a medical provider herself — she'd be comfortable detailing her breast cancer journey in ways others might not.

Governor Kevin Stitt vetoed a bill that would have required insurance to cover advanced breast cancer screenings for high-risk women. The bill had strong bipartisan support and was aimed at ...

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between ...

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

This decline was consistent across molecular subtypes, including luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)–enriched, and triple-negative breast cancer (TNBC).